All Articles

With nearly $1B in cash and a shrinking net loss, Janux is pushing its advanced prostate cancer drugs while its novel autoimmune therapy nears a key data reveal.

Stunning 120% revenue growth validates Senseonics' shift to in-house sales, but soaring costs and a widening net loss raise critical questions about its path to profitability.

With a $215M war chest and a runway into 2028, Corvus Pharmaceuticals is aggressively advancing its lead drug, soquelitinib, across cancer and immune diseases.

Outset Medical's Q2 results reveal a pivotal moment: a major HCA deal and stronger margins point to a new phase of sustainable growth in the dialysis market.

With a Q3 FDA submission for its novel epilepsy drug azetukalner imminent, Xenon leverages a massive cash runway to expand into neuropsychiatry and pain.

Clipper Realty's latest earnings reveal a stark divide. Record-breaking residential rents are being overshadowed by a major commercial property default.

Doximity's Q1 results reveal a company at a crossroads, sacrificing near-term profits for AI dominance. Engagement is soaring, but financials are strained.

A biotech firm has uncovered a self-perpetuating cycle that drives Alzheimer's from within the cell's mitochondria, and they've developed a drug to break it.

The strategic acquisition of The Mobility House North America by PowerFlex signals a major market consolidation, creating an end-to-end fleet solution powerhouse.

A Texas-based program offers a government-funded, no-cost path to six-figure IT jobs, providing a powerful new blueprint for closing the skills gap.

The iconic Canadian jeweler is delisting from the NYSE American. We dig into the financial pressures and strategic calculus behind this pivotal move.

Adastra's triple Databricks specialization isn't just an award; it's a rigorously tested validation of expertise that sets a new bar for trust in data.

Beyond the numbers, a record 210 organ transplants in July reveals a high-tech, human-powered system rewriting the rules of saving lives.

Colossal Foundation's rewilding fund offers cash and genetic tech to save seven species. But can a $250k budget tackle a $5M problem and prove its model?

International Bancshares reports steady half-year growth but a Q2 dip, revealing a strategy of proactive risk management and AI-driven efficiency.

As AI becomes universal, Smartly's ADVANCE gathers marketing's titans to answer the real question: Who will turn abundant data into winning intelligence?

With Amanda Morin's appointment, Compass High School signals a deepening of its specialized mission, setting a new benchmark for resilient, value-driven education.

A landmark study on equicenta® CTM shows it nearly triples a horse's odds of returning to performance, offering a ready-to-use solution that challenges the status quo.

With Safeway's grand opening, Thompson Thrift's $225M Gilmore project isn't just another development. It's a high-stakes test case for the future of suburban living.

As AI transforms search engines into 'answer engines,' the familiar digital marketing playbook is obsolete. One firm is pioneering a new strategy to survive.